ArticleCell discovery2022
Integrated proteogenomic characterization of medullary thyroid carcinoma.
Abstract read
In one paragraph
Article in Cell discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Single-cell transcriptomic analysis identifies decreasedTranslational cancer research · 2026Article
- Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.British journal of cancer · 2026Article
- Review
- Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.JCO precision oncology · 2026Article
- Proteogenomics: decoding cancer in multiple dimensions.MedScience · 2026Review
- Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer.Cell reports. Medicine · 2026Article
- Retroelements in thyroid cancer: epigenetic plasticity, dedifferentiation, and therapeutic opportunities.Reviews in endocrine & metabolic disorders · 2026Review
- Comprehensive Transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas.Scientific data · 2026Article
- Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.Nature communications · 2026Article
- Spatially resolved immune niches in thyroid cancer: from hot-cold-excluded ecosystems to precision immunotherapy.Frontiers in immunology · 2026Review
- Precision management of medullary thyroid carcinoma: a dynamic framework integrating biomarkers, genotyping, and risk stratification.Frontiers in endocrinology · 2026Review
- Comparative genomic and clinicopathological analysis uncovers contrasting molecular profiles of canine and human thyroid carcinomas.Communications biology · 2025Article
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Identification of Cancer-Associated Proteins in Colorectal Cancer Using Mass Spectrometry.Proteomes · 2025Article
- Identification of thyroid cancer biomarkers using WGCNA and machine learning.European journal of medical research · 2025Article
- TNXB modulates radiosensitivity of esophageal cancer through the ATM/P53 pathway.American journal of translational research · 2025Article
- Overview of management and therapeutic advances in medullary thyroid cancer.Endocrine oncology (Bristol, England) · 2025Review
- An Overview of Analytical Approaches to Cancer Proteogenomics.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Thyroid C-Cell Biology and Oncogenic Transformation.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Personalised immunotherapy strategies informed by single cell profiling in thyroid cancer: a mini review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Xiao Shi *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yaoting Sun *Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study; Research Center for Industries of the Future, Westlake University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0000-0001-7613-648X
Cenkai Shen *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yan Zhang *Department of Head and Neck Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Rongliang Shi *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Fan Zhang *Shanghai OE Biotech Co., Ltd, Shanghai, China.
Tian Liao *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Guojun LvDepartment of General Surgery, Changzhou Second People's Hospital, Changzhou, Jiangsu, China.
Zhengcai ZhuDepartment of Thyroid and Breast Surgery, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Lianghe JiaoDepartment of Thyroid and Breast Surgery, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Peng LiDepartment of Thyroid and Parathyroid Surgery, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Centre, Shenzhen, Guangdong, China.
Tiansheng XuShanghai OE Biotech Co., Ltd, Shanghai, China.
Ning QuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Naisi HuangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jiaqian HuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tingting ZhangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yanzi GuBiobank, Fudan University Shanghai Cancer Center, Shanghai, China.
Guangqi QinBiobank, Fudan University Shanghai Cancer Center, Shanghai, China.
Haixia GuanDepartment of Endocrinology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Weilin PuState Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences; Human Phenome Institute, Fudan University, Shanghai, China.
Yuan LiDepartment of General Surgery, Changzhou Second People's Hospital, Changzhou, Jiangsu, China.
Xiang GengDepartment of General Surgery, Changzhou Second People's Hospital, Changzhou, Jiangsu, China.
Yan ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tongzhen ChenDepartment of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shenglin HuangDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center; Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Zhikang ZhangShanghai OE Biotech Co., Ltd, Shanghai, China.
Shuting GeShanghai Luming Biological Technology Co., Ltd., Shanghai, China.
Wu WangShanghai OE Biotech Co., Ltd, Shanghai, China.
Weibo XuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Pengcheng YuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhongwu LuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yulong WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liang GuoDepartment of Head and Neck Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Yu WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. neck130@sina.com.
Tiannan GuoWestlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study; Research Center for Industries of the Future, Westlake University, Hangzhou, Zhejiang, China. guotiannan@westlake.edu.cn.ORCID http://orcid.org/0000-0003-3869-7651
Qinghai JiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. jq_hai@126.com.
Wenjun WeiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. kakarwen@163.com.
Funding
National Natural Science Foundation of China (National Science Foundation of China) 81772854National Natural Science Foundation of China (National Science Foundation of China) 82002830National Natural Science Foundation of China (National Science Foundation of China) 82072951Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 19ZR1410900Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 20YF1408200Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 22ZR1412800
Abstract
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy derived from parafollicular cells (C cells) of the thyroid. Here we presented a comprehensive multi-omics landscape of 102 MTCs through whole-exome sequencing, RNA sequencing, DNA methylation array, proteomic and phosphoproteomic profiling. Integrated analyses identified BRAF and NF1 as novel driver genes in addition to the well-characterized RET and RAS proto-oncogenes. Proteome-based stratification of MTCs revealed three molecularly heterogeneous subtypes named as: (1) Metabolic, (2) Basal and (3) Mesenchymal, which are distinct in genetic drivers, epigenetic modification profiles, clinicopathologic factors and clinical outcomes. Furthermore, we explored putative therapeutic targets of each proteomic subtype, and found that two tenascin family members TNC/TNXB might serve as potential prognostic biomarkers for MTC. Collectively, our study expands the knowledge of MTC biology and therapeutic vulnerabilities, which may serve as an important resource for future investigation on this malignancy.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.